Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus (Q40111393)

17 September 2017

title

Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus (English)

1 reference

17 September 2017

1 reference

1 reference

Raki M

1

1 reference

17 September 2017

Hakkarainen T

2

1 reference

17 September 2017

Bauerschmitz GJ

3

1 reference

17 September 2017

Särkioja M

4

1 reference

17 September 2017

Desmond RA

5

1 reference

17 September 2017

Kanerva A

6

1 reference

17 September 2017

Hemminki A

7

1 reference

17 September 2017

publication date

5 July 2007

1 reference

17 September 2017

1 reference

17 September 2017

volume

14

1 reference

17 September 2017

issue

19

1 reference

17 September 2017

page(s)

1380-1388

1 reference

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Modified adenoviruses for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

CD46 represents a target for adenoviral gene therapy of malignant glioma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Influence of the bystander effect on HSV-tk/GCV gene therapy. A review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

1 reference

7 January 2021

Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Herpes simplex virus thymidine kinase-green fluorescent protein fusion gene: new tool for gene transfer studies and gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

A simplified system for generating recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302992

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302992

1 reference

Dimensions Publication ID

17 September 2017

1000855787

0 references

1 reference